Chugai receives Japanese approval for Lunsumio & Polivy combo therapy for additional indication of relapsed or refractory large B-cell lymphoma: Tokyo Tuesday, March 24, 2026, 11: ...

With low dose starting at 1,290 per month, analysts are expecting a two-fold jump in the sale of GLP-1 units over the next ...

Data from the phase 3b STEP UP trial demonstrate that the 7.2 mg semaglutide dose provides superior weight reduction compared ...

In his complaint, Michael Wade Nance said his veins were so severely compromised that they were likely to blow and cause him ...

Early data from the first phase III trial of Lilly’s triple agonist show reductions in weight and HbA1c for patients with ...

Is it possible to train the body to resist seasonal allergies? That’s the hope promised by a new line of immunotherapy reviving an old treatment.

Dianthus Therapeutics (NASDAQ:DNTH) said it has made an “early go” decision to continue its CAPTIVATE Phase 3 trial ...

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and ...

Wegovy is a Food and Drug Administration-approved weight loss medication for people with obesity or those who are overweight with weight-related health conditions. In recent years, interest in ...

Roche Group AG’s RHHBY obesity drug push faces stiff competition after Genentech, a unit of Roche, reported Phase 2 results showing up to 10.7% weight loss—below expectations and lagging leading ...

Many people living with rheumatoid arthritis (RA) rely on long-term medications to manage joint pain, stiffness, and inflammation. A number of these treatments are given as subcutaneous injections, ...